VULCAN utilises network analysis of genome-wide DNA binding data to predict regulatory interactions of transcription factors. We benchmarked our approach against alternative methods and found improved performance in all cases. VULCAN analysis of estrogen receptor (ER) activation in breast cancer highlighted key components of the ER signalling axis and identified a novel interaction with GRHL2, validated by ChIP-seq and quantitative proteomics.
Introduction

Network Analysis of ChIP-seq to infer Transcription Factor (TF) activity
Usage of gene regulatory networks to analyse biological systems has witnessed an exponential increase in the last decade, due to the ease of obtaining genome-wide expression data [1] [2] [3] .
Recently, the VIPER approach to interrogate these network models has been proposed to infer transcription factor activity using the expression of a collection of their putative targets, i.e. their regulon [4] . In the VIPER algorithm, gene-level differential expression signatures are obtained for either individual samples (relative to the mean of the dataset) or between groups of samples, and regulons are tested for enrichment.
Several tools exist to integrate ChIP-seq binding events to increase statistical power and to support the interpretation of data. These methods typically provide information in the context of biological pathways and established gene sets [5, 6] or through motif analysis [7] . In contrast, we developed an extension of the VIPER algorithm, called " V irt U a L C hIP-seq A nalysis through N etworks" (VULCAN), to reveal and specifically analyse potential interactions of TFs in ChIP-seq experiments. Previously, the strategies employed by VIPER were limited to the analysis of transcription data. By developing VULCAN to overlay co-expression networks established from patient tumour data onto ChIP-seq data, we are able to provide candidate coregulators of the response to a given stimulus ( Figure 1 ). Unlike previous method, the results of our analysis are therefore focused on discovering tissue or disease specific interactions in the context of these networks. Further, as VULCAN builds on master regulator analysis, the output from the pipeline provides the end user with information in terms of the activity of potentially interacting TFs, rather than in terms of pathways. The combination of disease specific context and TF activity information presents a significant step forward in providing valuable information for the elucidation of on-chromatin interactions from ChIP-seq experiments over previous strategies.
The estrogen receptor as a model for systems biology
Breast cancer is the most common form of cancer in women in North America and Europe. The majority of breast cancers are associated with deregulated signalling by the Estrogen Receptor-alpha (ER), which drives tumour growth. ER is the key prognostic marker in the clinic and the target of the first lines of treatment in estrogen receptor positive (ER+) tumors.
ER-targeting pharmacological strategies include SERMs (Selective Estrogen Receptor
Modulators e.g. tamoxifen) and SERDs (estrogen receptor degraders, e.g. fulvestrant) and aromatase inhibitors that block the production of estrogens in the body [8] On activation, ER binds to promoter and enhancer regions containing Estrogen-Response Elements (ERE) [9] to stimulate the transcription of hundreds of genes [10, 11] . Gene expression is driven by both the recruitment of the basal transcription machinery to these loci and through longer range interactions [12] . Analysis of ER-target genes showed that many are proliferative in function and drive the growth of the tumour [13] On the treatment of ER+ cells with estra-2-diol (E2), ER recruits several cofactors to form a complex on the chromatin. FOXA1 is of particular interest as the protein shares nearly 50% of its genomic binding sites with ER and has been shown to operate as a pioneer factor before ER activation [14] . It is through FOXA1 and other cofactors [15, 16] , e.g. SRC-1, that ER is able to recruit RNA Polymerase II at the gene promoter sites in order to initiate transcription [17] .
Early studies have shown that, after stimulation with E2, ER binding to EREs can occur within minutes [18] . Maximum ER occupancy at promoters of target genes such as CTSD and TFF1 is achieved after 45' in MCF7 cells. Roughly 90' after estradiol treatment, ER is partially released from the promoters of the target gene, only to reoccupy the site again at 135' and release them at 180', in a 45' phase cyclical manner [19] . The 90' occupancy phase has been shown to be independent of new protein synthesis, and is therefore thought to operate at the post-translational level. This cyclic, proteasome-mediated turnover of unliganded and liganded ER-α on responsive promoters is an integral feature of estrogen signaling [20, 21] .
Given the three features discussed above, ER is a prime target for systems biology. By applying VULCAN to ChIP-seq time-course data of ER activation, our study provides new temporal insights into ER cofactors on a genome-wide scale.
Results
The development of VULCAN to infer changes in cofactor activity from differential ChIP-seq analysis using network analysis led to novel insights into key coregulators of the ER binding process. An implementation of VULCAN in R is available on Bioconductor.org [ https://bioconductor.org/packages/release/bioc/html/vulcan.html ] and the scripts to replicate our analysis are available as a supplementary Rmarkdown file. Unless otherwise specified, all p-values were Bonferroni-corrected.
Regulatory network analysis to detect ER cofactors VULCAN was developed in order to understand which TF or co-factors could be responsible for the temporal behavior of ER. To develop VULCAN, we combined co-expression networks, established from breast cancer tumour biopsy transcriptional data, with a modified version of the VIPER algorithm [4] to enable master regulator analysis on differential binding signatures acquired from ChIP-seq analysis.
We generated co-expression networks using the most recent implementation of ARACNe [22] on the METABRIC dataset [23] and the independent TCGA dataset [24] . Briefly, ARACNe generates gene networks by estimating putative regulatory interactions between transcription factors and target genes using mutual information between gene expression profiles. As an example, Figure 1C shows an ARACNe-inferred targets of ESR1. The sets of targets of each TF (i.e. its regulon) were merged in a genome-wide transcriptional regulation network, as shown in a minimal diagram in Figure 1D .
Master regulator analysis [25] is an algorithm developed to identify transcription factors whose regulon is enriched within a list of differentially expressed genes. VULCAN extends the VIPER approach to use differential binding profiles rather than differential expression profiles. In this way, VULCAN can test the enrichment of TF regulons in ER occupancy signatures derived from ChIP-seq experiments ( Figure 1E ).
Comparison of VULCAN to existing methods
Comparing VULCAN's Mutual Information networks to Partial Correlation networks
VULCAN uses mutual information networks like VIPER [4] . To test the robustness of our approach to different underlying networks, we compared mutual information networks with partial correlation networks using different correlation thresholds. We generated several partial correlation networks from the TCGA Breast Cancer data using the same input as the ARACNe network used by VULCAN. We tested the overlap of every partial correlation network with the ARACNe network using the Jaccard Index (JI) criterion ( Suppl. Figure 33 ). Finally, we show how the Jaccard Index between partial correlation networks and the ARACNe network is always significantly higher than expected by selecting random network edges ( Suppl. Figure 34 ). This confirms previous observations that partial correlation and mutual information networks are highly similar [26] Comparing VULCAN with alternative methods for target enrichment analysis
We compared VULCAN's Gene Set Enrich ment Analysis (GSEA) approach [27] with three independent methods previously applied to benchmark VIPER [4] . The first implemented a t-test based method, which takes the targets of a TF and integrates their p-value in a specific contrast. The method is similar to VIPER but involves a Fisher p-value integration step. The integrated test lacks stringency and results in nearly all regulons as significantly enriched ( Suppl. Figure 35 ). Second, we implemented a fraction of targets method, defining for every TF the fraction of their targets that are also differentially bound. This alternative to VULCAN ignores the MI strength of interaction and the individual strengths of differential bindings, reducing the resolving power of the algorithm ( Suppl. Figure 36 ). Finally, we compared to a Fisher's Exact Method, which assesses the overlap between networks and significant differential binding. This method is too stringent (as observed in the original VIPER paper) [4] and even without p-value correction there are no significant results, even at low stringency, demonstrating the low sensitivity of the using a Fisher's Exact Method method ( Suppl. Figure 37 ). In summary, VULCAN outperformed all three alternative methods we tested (t-test based; fraction of targets method; and Fisher's Exact Method) in our dataset.
Comparing VULCAN with Online Tools (GREAT, ISMARA & ChIP-Enrich)
To further validate our method, we compared the output of our GSEA analysis with different versions of promoter-enrichment approaches implemented by GREAT [5] , ISMARA [7] and ChIP-Enrich [6] . The VULCAN analysis shows a significant overlap in terms of detected pathways with the GREAT method ( Suppl. Figure 38 ). ChIP-Enrich identifies enrichme nt of a number of TFs also predicted by VULCAN, but it fails to identify ESR1 as the top transcription factor affected by our experiment ( Suppl. Figure 39 ). ISMARA succeeds at identifying ESR1 using a motif-based analysis, but does not identify other candidate binding TFs ( Suppl. Figure   40 ). In summary, VULCAN outperforms both ISMARA and ChIP-Enrich, and significantly overlaps with GREAT, but provides additional value through inference of TF factor activity.
VULCAN analysis of ER activation
Differential Binding Analysis
We performed four replicated ChIP-seq experiments for ER at three timepoints: 0, 45 and 90' after estradiol treatment (Figure 2 ) in the MCF7 breast cancer cell line . The binding profile of ER at each time point was then compared between time points using differential binding analysis. Differential binding analysis ( Figure 2B ,C ) identified 18,900 statistically significant binding events at 45' (p < 0.05). We observed the previously reported reduction of ER binding at 90' [20] on a genome-wide level (17,896 significant binding events), but with a smaller amplitude than previous gene-specific assays [21] . A potential cause for the smaller amplitude we observed in ER cycling may relate to the fact that ChIP-seq is not inherently quantitative, and hence the typical normalisation strategies applied to ChIP-seq data are likely to suppress global changes [28, 29] . We therefore validated the ER binding behaviour with ChIP-qPCR ( Figure 2A ) and observed the same reduction in amplitude at specific binding events as was predicted by ChIP-seq. Another potential reason for the difference in amplitude was we did not treat α -Amanitin prior to treatment with E2 [21] as this perturbation would further separate the e x perimental condition from clinical interpretation .
We performed motif enrichment analysis (HOMER software) on ER binding sites detected by differential binding analysis. This analysis confirmed a strong enrichment for a single element, ERE, bound at both 45 and 90', with a corrected p-value of 0.0029 ( Figure 3F ).
When clustered according to peak intensity, samples cluster tightly in two groups: treated and untreated ( Suppl. Figures 2, 3 and 4 ), but treatment at 45 and 90' is detectably different on a genome-wide scale, as highlighted by Principal Component Analysis ( Suppl. Figures 5 and 6 ).
VULCAN groups genes by temporal dynamics of ER binding
We leveraged the information contained in mutual information networks to establish TF networks enriched in the differential binding patterns induced by estradiol. From our temporal analysis of ER binding, we established four classes of binding pattern: early responders, repressed transcription factors, late responders and candidate cyclic genes ( Figure 3 ) .
Using VULCAN, we defined TF network activity of occupied regulatory regions ( Figure   3A ) according to the binding of ER within their promoter and enhancer regions (limited to 10kb upstream of the Transcription Starting Site to ensure gene specificity). We define as early responders TFs whose network is upregulated at both 45 and 90' ( Figure 3B ); these genes include AR, SP1 and CITED1. TFs with opposite behaviour (namely TFs whose negative/repressed targets in the ARACNe model are occupied by ER), or "repressed TFs", include GLI4, MYCN and RAD21 ( Figure 3C ). Some TFs appear to have their targets bound at 45', but then unoccupied at 90'. This "updown" behaviour is consistent with the cyclic properties of certain components of the ER DNA-binding complex observed previously, and therefore we dubbed them "candidate cyclic TFs" ( Figure 3D ). We also define a "late responders" category, defined as TFs active at 90 but not at 45'. While this category exists, and notably contains both ESR1 and the known ESR1 interactor GATA3, it is just below the significance threshold at 45'
Validating VULCAN results on independent data
We repeated our TF network activity analysis of ER activation ( Figure 3A As a negative control, we used a different context ARACNe network, derived from the TCGA AML dataset. This network shows globally weaker enrichment scores and a weak positive correlation with the results obtained through breast cancer regulatory models ( Suppl.
Figure 22
).
Pathway analysis of regulatory region binding
We performed a Gene Set Enrichment Analysis [27] and an associated Rank Enrichment Analysis [4] using the differential binding at gene regulatory regions (with time 0 as reference).
Individual differential binding signatures for GSEA were calculated using a negative binomial test implemented by DiffBind [30] . The collective contribution of differentially bound sites highlights several ER-related pathways [31] [32] [33] ( Suppl. Figure 23 ) in both the GSEA and aREA analyses. The strongest upregulated pathway in both time points ( Table S2 and S5 ) was derived via RNA-seq in an MCF7 study using estradiol treatment [32] , confirming the reproducibility of our dataset.
Validating VULCAN results by quantitative proteomics
We tested the performance of VULCAN against a complementary experimental approach called RIME [34] combined with TMT [35] (qPLEX-RIME), which aims at identifying interactors of ER within the ER-chromatin complex. We generated ER qPLEX-RIME data from MCF7 cells treated with estradiol at both 45 and 90' and compared this with the VULCAN dataset, with the aim of identifying TFs upstream of the observed differential binding ( Suppl. Figure 31 ). We found known ESR1 interactors with both methods, namely HDAC1, NCOA3, GATA3 and RARA with positive Network Enrichment Score (NES) [4] , implying the TF's regulon is over-represented within the differentially bound genes. Conversely, GRHL2 was discovered with a negative NES. A negative NES implies the regulon is either significantly depleted within the set of differentially bound genes or that TF is established by ARACNe as having a negative correlation to the genes regulated at these differentially bound sites.
The GRHL2 Transcription Factor
In our analysis of ER dynamics, the GRHL2 transcription factor stood out. In both the METABRIC and TGCA networks, GRHL2 was significantly repressed; yet in our proteomics analysis, the protein was significantly increased. GRHL2 is a transcription factor that is important for maintaining epithelial lineage specificity in multiple tissues [36, 37] . It has previously been predicted to exist in ER-associated enhancer protein complexes [38] , but its function in the ER signalling axis is unknown. Therefore, we set out to experimentally validate GRHL2 as an ESR1 cofactor, possibly with repression properties for the ER complex.
Our analysis shows t hat the genes occupied by the ER complex do not form part of the GRHL2 regulon, using both TCGA-derived and METABRIC-derived regulatory models. Our analysis highlights the small overlap between the ESR1 (Estrogen Receptor) and GRHL2 networks ( Suppl. Figure 28 ), hinting at complementary signals not dependent on global network overlaps. In fact, there is only a weak, positive correlation between ESR1 and GRHL2 expression in the TCGA breast cancer dataset ( Suppl. Figure 29 ) and also in the METABRIC breast cancer dataset ( Suppl. Figure 30 ). Furthermore, GRHL2 has a visibly lower variance than ESR1: it does not change significantly in different PAM50 subtypes, although it is lower in normal compared to malignant tissue.
The low overlap between networks and the low correlation in expression profiles could be explained by the fact that GRHL2's role may not be related to its function as a transcription factor; rather, it may be controlled by other mechanisms like phosphorylation, subcellular localisation or on-chromatin interactions.
GRHL2 activity before and after stimulation with E2
Differential ChIP-seq analysis of GRHL2 binding between 0 and 45' indicated that GRHL2
binding is altered on treatment with E2 ( Figure 5A ) . VULCAN analysis of the GRHL2 differential binding showed a consistent Network Enrichment Score for both the TCGA-and METABRIC-derived networks for ER, but not for FOXA1 or GRHL2 ( Figure 5B ) . Individual analysis of peaks show that typically ER promoter sites, e.g. RARa, were not the target of this redistribution of GRHL2, as these sites were occupied by GRHL2 before E2 stimulation. Motif analysis of the sites within increased GRHL2 occupancy showed enrichment for the full ERE (p-value = 1 x 10 -86 ) and the GRHL2 binding motif (p-value = 1 x 10 -31 ).
qPLEX-RIME analysis of GRHL2 interactions showed high coverage of the bait protein (>59%) and, in both the estrogen-free and estrogenic conditions, high levels of transcription-related protein interactors including HDAC1 (p-value = 6.4 x 10 -9 ), TIF1A (p-value = 6.4 x 10 -9 ), PRMT (p-value = 6.4 x 10 -9 ) and GTF3C2 (p-value = 4.6 x 10 -9 ). P-values given for estrogenic conditions and estrogen-free conditions were comparable. The only protein differentially bound to GRHL2 in estrogen-free versus estrogenic conditions was ER.
The specific nature of the detected ER-GRHL2 interaction suggests that ER does not regulate or interact with GRHL2 through the recruitment of alternative cofactors. This implies instead that ER recruits GRHL2 to certain genomic loci for a specific function. We therefore undertook a comparison of GRHL2 binding with public datasets. (Fig ure 5C ). Our analysis showed that GRHL2 sites that responded to E2 were enriched for ER binding sites (in agreement with our qPLEX-RIME data) and FOXA1 (compatible with either an ER interaction or the previously reported interaction with MLL3 [38] ). To establish, therefore, if the reprogramming of GRHL2 was primarily related to a transcriptional function or the previously described interaction with MLL3, we overlapped our GRHL2 data with that of published H3K4me1/3 [38] and P300 [39] cistromes. While H3K4me occupancy was consistent between conditions, we found P300 binding to be enriched at the E2 responsive GRHL2 sites. A more detailed analysis of the GRHL2 overlap with P300 sites showed the greatest co-occupancy of GRHL2/P300 sites was when both TFs were stimulated by E2 ( Figure 5D ). Moreover , overlap of GRHL2 peaks with ER ChIA-PET data [ENCSR000BZZ] showed that the GRHL2 responsive sites were enriched at enhancers over promoters ( Figure 5E ).
These findings suggested that the GRHL2-ER interaction was involved in transcription at ER enhancer sites. To explore this concept further, we investigated the transcription of enhancer RNAs at these sites using publicly available GRO-seq data [40] [GSE43836] ( Figure   5F ). At E2 responsive sites , eRNA transcription was strongly increased by E2 stimulation; by contrast, eRNA transcription was largely independent of E2 stimulation when the entire GRHL2 cistrome was considered. Analysis of a second GRO-seq dataset, GSE45822, corroborated these results (Suppl. Figure S92) .
To further explore how GRHL2 regulates ER enhancers, we measured eRNA expression at the GREB1, TFF1 and XBP1 enhancers after over-expression of GRHL2. At TFF1 and XBP1, increased GRHL2 resulted in reduced eRNA transcription ( Figure 6 ) (p < 0.05, paired-sample, t-test). Conversely, eRNA production at the TFF1, XBP1 and GREB1 enhancers was moderately increased after GRHL2 knockdown (Suppl. Figure 106) . Combining data from all three sites established the effect as significant by paired-sample rank test (p = 0.04, one-tailed paired-sample, wilcoxon test). Collectively, these data demonstrate that GRHL2 constrains specific ER enhancers.
Analysis of mRNA expression levels of TFF1, XBP1 and GREB1 by RT-qPCR revealed that overexpression of GRHL2 also led to a significant reduction in TFF1 and XBP1 (p < 0.05, paired-sample, t-test), while knockdown of GRHL2 led to a significant increase in GREB1 transcription (p < 0.05, paired-sample, t-test) (Suppl. Figure 107 ) . By developing VULCAN, we have been able to rediscover known cofactors of the estradiol-responsive ER complex and predict and experimentally validate a novel protein-protein interaction.
Discussion
Reprogramming of GRHL2 by ER
In the 4T1 tumour model, GRHL2 was found to be significantly downregulated in cells that had undergone EMT [36] . The same study showed that knockdown of GRHL2 in MCF10A -an ER-negative cell line -lead to loss of epithelial morphology. Overall, this suggested that the GRHL2 transcription factor plays an essential role in maintaining the epithelial phenotype of breast cells. Similar results were observed with the MDA-MB-231 model, where expression of GRHL2 resulted in reversal of EMT [37] . This result has been recapitulated in hepatocytes, where GRHL2 was found to suppress EMT by inhibiting P300 [41] Survival data for ER+ breast cancer (KMplotter, use gene expression, p=0.001) and ER-(KMplotter, use gene expression, p=0.035) shows that high GRHL2 has a negative impact on survival time in both contexts. The ability to suppress EMT has also been noted in prostate cancer, another cancer driven by a steroid hormone receptor (AR), and the genes regulated by GRHL2 are linked to disease progression [42] .
Combined, these earlier data indicate a significant role for GRHL2 in the progression of breast cancer, but its role in the ER signalling axis has, until now, been unknown. Here, we
show that GRHL2 constrains activity at a subset of ER enhancers. Overexpression of GRHL2 resulted in a significant decrease in eRNA production at the TFF1 and XBP1 enhancers and, in agreement with previous studies that correlate eRNA transcription with gene expression [43] [44] [45] , we found the measured eRNA decrease was concurrent with a significant downregulation in the expression of the corresponding gene.
These results are consistent with previous findings that GRHL2 inhibits P300 [41] and, while the ER complex results in the activation of eRNA transcription at these sites, that GRHL2 plays a role in fine-tuning or modulating this process.
In breast cancer, GRHL2 has previously been shown to directly interact with FOXA1, which may contribute to tethering of the histone methyltransferase MLL3 and, consequently, epigenetic marks at GRHL2/FOXA1 binding sites [38] . Our analysis, however, showed no particular enrichment for H3K4me1/3 marks at E2 responsive G RHL2 sites compared to other GRHL2 binding sites and our proteomic analysis of interactors showed a strong association with proteins related to transcription. Therefore, while GRHL2 ChIP-seq analysis shows that GRHL2
is already bound to a proportion of FOXA1 sites before treatment of cells with E2, we still observed an increase in GRHL2 binding at 45'. We proposed that these ER responsive sites are related to a role of GRHL2 in a transcriptional process independent of its interaction with MLL3. This was supported by evidence of a significant overlap with binding of the coactivator P300 and a pronounced increase in eRNA transcription on activation at E2 responsive GRHL2 sites.
Conclusion
VULCAN is built on state-of-the-art network analysis tools previously applied to RNA-seq data.
By adapting network-based strategies to ChIP-seq data, we have been able to reveal novel information regarding the regulation of breast cancer in a model system.
The VULCAN algorithm can be applied generally to ChIP-seq for the identification of new key regulator interactions. Our method provides a novel approach to investigate chromatin occupancy of cofactors that are too transient or for which no reliable antibody is available for direct ChIP-seq analysis.
VULCAN enabled us to identify the reprogramming of GRHL2 by the ER on stimulation with E2. Further analysis showed the process to be unrelated to the previously reported interaction with FOXA1 and MLL3 [38] . Our conclusion, therefore, is that GRHL2 has a second, previously undescribed, role: negatively regulating levels of transcription at estrogen responsive enhancers (Figure 7) . Given the central role of the ER in breast cancer development and GRHL2's own ability to regulate EMT, the discovery that ER recruits GRHL2, leading to the constraint of eRNA transcription, is an important step in enhancing our understanding of breast cancer and tumourigenesis. 
Methods
ChIP-Seq
Frozen samples were processed using established ChIP protocols [46] to obtain DNA fragments of~300 bp in length. The libraries were prepared from the purified DNA using a Thruplex DNA-seq kit (Rubicon Genomics) and sequenced on the Illumina HiSeq Platform.
Sequencing data is available from Gene Expression Omnibus, accession GSE109820.
Differential binding analysis
Sequencing data was aligned using BWA [47] to the human genome (hg19). Reads from within the DAC Blacklisted Regions was removed before peak calling with MACS 2.1 [48] on default parameters. The aligned reads and associated peak files were then analyzed using DiffBind [30] to identify significant changes in ER binding.
Gene Set Enrichment Analysis (GSEA)
Gene Set Enrichment Analysis (GSEA) was performed as described by Subramanian et al . [49] using the curated pathway collection (C2) from MSIGDB v 5.0 with 1000 set permutations for each pathway investigated, followed by Benjamini Hochberg P-value correction.
Motif analysis
Motif analysis of the binding regions was undertaken with Homer v4.4 [50] using default parameters. Motif logo rendering was performed using Weblogo v2.8.2 [51] VULCAN analysis
We reconstructed a regulatory gene network using ARACNe-AP as described by Alvarez [26] .
RNA-Seq breast cancer data was downloaded from TCGA on January 2015 and VST-Normalized as described by Anders and Huber [52] . The ARACNe transcriptional regulation network was imported into R using the viper BioConductor package and it was interrogated using the differential binding profiles from our ChIP-Seq experiment as signatures, qPLEX-RIME Samples were prepared as previously described for RIME [34] , protocol was modified to include TMT isobaric labels for quantification (manuscript under review). qPLEX-RIME data and analysis pipeline is available as part of the supplementary Rmarkdown.
TF Binding Overlap
Publically available data was downloaded as described in the source publication [38] [39] [40] 53] and overlap was calculated with bedtools (v2.25.0). Presented data was normalised as a percentage of GRHL2 sites.
Code availability
Code for data analysis is provided as an Rmarkdown document and supporting data is avalible A: ChIP-Seq analysis from multiple conditions is undertaken to generate cistrome data at multiple timepoints (or conditions). B: Binding events are then compared using differential binding analysis to establish log-fold change values for individual binding events between each timepoint. C: ARACNe-AP infers all pairwise TF-target coexpression. In the example, the TCGA breast dataset is shown to infer A putative target that is correlated with ESR1. D: Minimalistic representation of the ARACNe-AP network, highlighting negative and positive regulation of targets by transcription factors. E: All the targets of a specific TF are divided in positive and negative, and tested on a differential binding signature through the msVIPER algorithm 4 Figure 2 : Dynamic behaviour during early activation of ER ChIP-qPCR of the TFF1 gene (A) at 3 time points shows increased binding of ER at 45 minutes after MCF7 cells are stimulated by estra-2-diol. The previously reported maximum is followed by a decrease in the TFF1 promoter occupancy at 90 minutes. P-values are generated by one-tailed t-test. The maximal point at 90 minutes was identified as an outlier ( > median + 2 x IQR); however removal did not alter the significance of results. (B) Differential binding analysis of ChIP-Seq data at three time points to monitor the activation of ERa. The ER a strong increase in binding at 45 minutes vs. 0 minutes (C) and the majority of sites still display binding at 90 minutes. Overexpression of GRHL2 in MCF7 resulted in a reduction of eRNA transcribed from the GREB1, TFF1 and XBP1 enhancers. The effect was significant at TFF1 and XBP1 enhancers (p < 0.05, Wilcoxon paired-test).
Figure Legends
Figure 7: Overview of the role of GRHL2 in ER activation
On activation of the ER by the ligand E2 the protein is released from a complex containing HSPs and translocates to the nucleus. The holo-ER dimer forms a core complex at Estrogen Response Elements (ERE) with FOXA1 (pioneer factor) and GATA3. ER further recruits P300 and GRHL2. GRHL2 has an inhibitory effect on P300 (a transcriptional activator interacting with TFIID, TFIIB, and RNAPII) thereby reducing the level of eRNA transcription at enhancer sites. Overexpression of GRHL2 further suppresses transcription, while knockdown of GRHL2 reverses the process.
